Premature ovarian failure: predictability of intermittent ovarian function and response to ovulation induction agents

被引:33
作者
Bidet, Maud [1 ]
Bachelot, Anne [1 ]
Touraine, Philippe [1 ]
机构
[1] GH Pitie Salpetriere, Dept Endocrinol & Reprod Med, F-75651 Paris 13, France
关键词
anti-Mullerian hormone; gonadotropins; ovarian function; pregnancy; premature ovarian failure;
D O I
10.1097/GCO.0b013e328306a06b
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Purpose of review To summarize our current knowledge about the predictability of intermittent ovarian function and the response to ovulation induction agents in patients with premature ovarian failure. Recent findings In addition to clinical, histological or ultrasonographic features, a new biological marker anti-Mullerian hormone, was evaluated as a marker for ovarian reserve in premature ovarian failure patients with encouraging results. Moreover, even if no treatment has proven to be effective enough to restore ovarian function, a recent study has presented a therapeutic protocol leading to a significant increase in ovulation and a higher pregnancy rate. Summary Intermittent ovarian function can be spontaneously observed in premature ovarian failure patients. Clinical, biological and ovarian ultrasonographic features may allow an assessment of the presence of ovarian activity, but are not necessarily correlated with a higher ovulation or pregnancy rate. Nevertheless, it appears essential to characterize these patients to determine whether some of them could be candidates who benefit from a particular therapeutic strategy, although most such strategies have not yet demonstrated their efficiency.
引用
收藏
页码:416 / 420
页数:5
相关论文
共 37 条
[1]   Premature ovarian failure: an update [J].
Anasti, JN .
FERTILITY AND STERILITY, 1998, 70 (01) :1-15
[2]  
ANASTI JN, 1994, FERTIL STERIL, V62, P726
[3]   RETRACTION: RETRACTED: Induction of ovulation in idiopathic premature ovarian failure: a randomized double-blind trial (Retraction of Vol 15, Pg 215, 2007) [J].
Badawy, A. ;
Goda, H. ;
Ragab, A. .
REPRODUCTIVE BIOMEDICINE ONLINE, 2023, 47 (03) :215-219
[4]   Premature ovarian failure [J].
Beck-Peccoz, Paolo ;
Persani, Luca .
ORPHANET JOURNAL OF RARE DISEASES, 2006, 1 (1)
[5]  
Check J H, 2006, Clin Exp Obstet Gynecol, V33, P71
[6]   Characterization of idiopathic premature ovarian failure [J].
Conway, GS ;
Kaltsas, G ;
Patel, A ;
Davies, MC ;
Jacobs, HS .
FERTILITY AND STERILITY, 1996, 65 (02) :337-341
[7]   Relationship between serum mullerian-inhibiting substance and other reproductive hormones in untreated women with polycystic ovary syndrome and normal women [J].
Cook, CL ;
Siow, Y ;
Brenner, AG ;
Fallat, ME .
FERTILITY AND STERILITY, 2002, 77 (01) :141-146
[8]   Antimullerian hormone serum levels: a putative marker for ovarian aging [J].
de Vet, A ;
Laven, JSE ;
de Jong, FH ;
Themmen, APN ;
Fauser, BCJM .
FERTILITY AND STERILITY, 2002, 77 (02) :357-362
[9]   Regulation of ovarian function: the role of anti-Mullerian hormone [J].
Durlinger, ALL ;
Visser, JA ;
Themmen, APN .
REPRODUCTION, 2002, 124 (05) :601-609
[10]   Serum anti-Mullerian hormone is more strongly related to ovarian follicular status than serum inhibin B, estradiol, FSH and LH on day 3 [J].
Fanchin, R ;
Schonäuer, LM ;
Righini, C ;
Guibourdenche, J ;
Frydman, R ;
Taieb, J .
HUMAN REPRODUCTION, 2003, 18 (02) :323-327